#USA #Franklin Lakes #IVDR #BD MAX™ System #VIASURE

BD Expands BD MAX™ System Menu with New VIASURE Assays

BD (Becton, Dickinson and Company), a top-tier global medical technology firm, announced a significant expansion of its diagnostic capabilities with the introduction of new, IVDR-certified VIASURE assays. This expansion focuses on enhancing the BD MAX™ System, particularly in diagnosing respiratory conditions and sexually transmitted infections (STIs). The partnership with Certest Biotec plays a crucial role in the development and rollout of these assays, which are now being adopted in various clinical environments across Europe.

The newly certified assays added to the BD MAX™ System include:

• - VIASURE Respiratory Virus Extended Mix Real Time PCR Detection Kit: This advanced kit can identify a range of respiratory viruses, including SARS-CoV-2, influenza types A and B, respiratory syncytial virus (RSV), parainfluenza virus, human coronavirus, metapneumovirus, and adenovirus. All these viruses can be detected from just a single nasopharyngeal swab, significantly simplifying the testing process.

• - VIASURE HSV-1, HSV-2 and Treponema pallidum Assay: This assay enables the detection of herpes simplex viruses (both types 1 and 2) alongside the bacteria responsible for syphilis, Treponema pallidum. It uses swabs from anogenital and oral lesions to identify these pathogens effectively.

Philippe Villiard, Vice President of BD Diagnostic Solutions in Europe, expressed the excitement surrounding the integration of these assays into BD’s existing diagnostic menu. He stated, "With these two assays, we are adding clinically relevant, targeted molecular panels to our already broad respiratory and STI menu." This remark highlights BD's commitment to delivering cutting-edge diagnostic solutions that facilitate rapid and accurate detection of infectious diseases.

The BD MAX™ System itself is a fully automated molecular platform capable of processing up to 24 samples in a single run. It combines real-time PCR technology with automated processes for nucleic acid extraction, amplification, and detection, all streamlined into one workflow. This sophisticated design produces results in approximately three hours, with less than a minute of hands-on time required per sample. Such efficiency is crucial as it provides healthcare professionals with timely information necessary for making informed treatment decisions, ultimately improving patient care.

Nelson Fernandes, CEO of Certest, shared his enthusiasm about the continuing partnership with BD, stating, "Our collaboration, which began in 2017, has only strengthened over time. We are confident that our joint efforts will yield remarkable projects in the near future." This statement underscores the ongoing commitment of both companies to innovate in the field of medical diagnostics.

BD has established itself as one of the largest global medical technology companies, dedicated to advancing healthcare by improving medical discovery, diagnostics, and the delivery of care. The organization prides itself on supporting healthcare providers on the frontlines by offering innovative technologies and solutions. With a workforce of over 70,000, BD strives to enhance processes for clinicians, enabling laboratories to accurately detect diseases and empowering researchers to develop next-generation diagnostics and therapeutics.

The introduction of these new VIASURE assays is not just a step forward for BD and Certest, but a significant leap for medical diagnostics in respiratory and STI detection. By enhancing their testing capabilities, these two companies are working toward a future where healthcare becomes even more responsive and effective in combating infectious diseases.

For more information about BD and its innovative solutions, visit bd.com. You can also connect with them on LinkedIn and Twitter to stay updated on the latest advancements in medical technology.